On the basis of the above considerations, in the present study we tested a commercially available FCBA kit designed to detect the BCR-ABL1 fusion protein on primary CML samples in order to determine the applicability, reliability, specificity and rapidity of this method for both diagnosis and monitoring of CML patient burden within the initial months of therapy. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.